Sequoia Sciences has an unparalleled collection of structurally diverse natural product compounds isolated from plants.  From this collection, Sequoia has identified compounds that may potentially provide new and alternative treatments for acute bacterial infections and chronic infections involving bacterial biofilms. Based upon these results, Sequoia Sciences is embarking on preclinical development programs with the goals of addressing the unmet medical needs for the treatment of lung infections in cystic fibrosis patients and recurrent urinary tract infections. These programs consist of small molecules targeting gram-positive and gram-negative bacterial infections and vaccines for the treatment and prevention of recurrent urinary tract infections. To this purpose, we are engaged in collaborations with other laboratories, universities, and companies.  Our goal is to improve the quality of life for those individuals significantly affected by acute bacterial infections and chronic infections involving bacterial biofilms.

Presentations | See All

Sequoia Sciences Invited to Present at the 2011 Phytochemical Society of North America Meeting.

Mark O'Neil-Johnson, VP of Analytical Chemistry, is an invited speaker at the annual meeting for the Phytochemical Society of North America (PSNA), to be held in Hawaii from December 10-14. This meeting will celebrate the 50th Anniversary of the Phytochemical Society of North America.

Sequoia Sciences Invited to Present at the 2012 Zing Conference on Natural Products

Mark O'Neil-Johnson, VP of Analytical Chemistry, will participate in this international conference on Natural Product Synthesis and Biosynthesis. The conference will be held in Puerto Calero, Lanzarote, Spain, February 10-13, 2012.

Sequoia Sciences Invited to Present at the 2012 Gordon Research Conference on Marine Natural Products

Mark O'Neil-Johnson, VP of Analytical Chemistry, is an invited speaker at the Gordon Research Conference on Marine Natural Products, to be held in Ventura, California from February 26 - March 2, 2012.

Recent Publications | See All

January 2012: Starks, C.M.; Williams, R.B.; Rice, S.M.; Norman, V.L.; Lawrence, J.A.; Goering, M.G.; O'Neil-Johnson, M.; Hu, JF; Eldridge, G.R. "Cytotoxic Cyclohexene Derivatives from Monanthotaxis congoensis." Phytochemistry, 2012, 74, 185-189.

January 2012: Williams, R.B.; Martin, S.M.; Hu, J.F.; Garo, E.; Rice, S.M.; Norman, V.L.; Lawrence, J.A.; Hough, G.W.; Goering, M.G.; O'Neil-Johnson, M.A.; Eldridge, G.R.; Starks, C.M. "Isolation of Apoptosis-Inducing Stilbenoids from Four Members of the Orchidaceae Family." Planta Medica, 2012, 78(2), 160-165.

May 2011: Olson, K.M.; Starks, C.M.; Williams, R.B.; O'Neil-Johnson, M.; Huang, Z.; Ellis, M., Reilly, J.; Eldridge, G.R. "Novel Pentadecenyl Tetrazole Enhances Susceptibility of MRSA Biofilms to Gentamicin", Antimicrobial Agents and Chemotherapy, 2011, 55(8), 3691-3695. This publication describes a synergistic combination of antibacterials against MRSA biofilms that is superior to clinically used MRSA antibiotics.

August 2010: Williams, R.B.; Hu, J.F.; Olson, K.M.; Norman, V.L.; Goering, M.G.; O'Neil-Johnson, M.; Eldridge, G.R.; Starks, C. "Antibiotic Indole Sesquiterpene Alkaloid from Greenwayodendron suaveolens with a New Natural Product Framework" Journal of Natural Products, 2010, 73, 1008-1011. This publication describes a novel antibacterial with an MIC90 of 4 ug/ml against clinical isolates of MRSA.